AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01972438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Control Intervention
Study NCT01972438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control Intervention
Study NCT04493931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.
Study NCT04493931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to gepotidacin
Description: Placebo matching to gepotidacin tablets will be administered orally.
Study NCT01114204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT01114204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study NCT01391520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study NCT01391520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study NCT02138630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Study NCT02138630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar capsule
Study NCT01261702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline IV
Study NCT01261702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulphate
Description: The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
Study NCT01090570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules
Study NCT01090570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLX3397
Description: Once-daily oral capsules
Study NCT01543243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
Study NCT01543243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration B
Description: Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4.
Study NCT02238379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 International Units of Oxytocin in a Nasal Spray
Study NCT02238379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
Study NCT00604526 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds
Description: Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months.
Study NCT01040858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Strategy Training
Description: Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
Study NCT01040858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparison group
Description: Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
Study NCT02157779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
Study NCT00836381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release (ER) 4mg
Description: Tolterodine extended-release (ER) 4mg once daily for 12 weeks
Study NCT00836381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical Placebo once daily
Study NCT03425396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline tablets
Description: Oral Omadacycline
Study NCT02157779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Intervention
Description: Includes individual therapy sessions using supportive and problem-solving strategies.
Study NCT03211364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral mobilization
Description: Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
Study NCT03211364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scapular mobilization
Study NCT03222193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRP
Description: 3 months of TRP tongue retraining
Study NCT00778583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg capsules
Study NCT00778583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 mg capsules
Study NCT04111003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: administering local anesthesia in the region of the planned restorative procedure
Study NCT04111003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia
Description: administering local anesthesia in the region of the planned restorative procedure
Study NCT04111003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth restored using SFRC filling
Description: Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
Study NCT04111003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restored using Ceramic indirect endocrown
Description: Restoration of an endodontically treated molar using a ceramic indirect restoration
Study NCT04051164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Technique
Description: PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week.
Study NCT04051164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
Study NCT03546894 — intervention group
Intervention type: DRUG
Intervention: Brigatinib
Description: Brigatinib tablets.
Study NCT03546894 — intervention group
Intervention type: DRUG
Intervention: Alectinib
Description: Alectinib capsules.
Study NCT03546894 — intervention group
Intervention type: DRUG
Intervention: Ceritinib
Description: Ceritinib capsules.
Study NCT03546894 — intervention group
Intervention type: DRUG
Intervention: Lorlatinib
Description: Lorlatinib capsules.
Study NCT03546894 — intervention group
Intervention type: DRUG
Intervention: Any FDA Approved ALK Inhibitors
Description: FDA approved ALK inhibitors available for treatment.
Study NCT01162681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once a week for up to 52 weeks
Study NCT01162681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: Low dose given subcutaneously once a week for up to 52 weeks
Study NCT01162681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once every 4 weeks for up to 52 weeks
Study NCT01162681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
Study NCT01588626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: tablet
Study NCT03425396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin capsules
Description: Oral Nitrofurantoin
Study NCT01663090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Study NCT04832607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multivirus (CMV, EBV, AdV)-specific T cells
Description: Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
Study NCT04832607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multivirus (CMV, EBV, AdV)-specific T cells
Description: Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
Study NCT03537976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static Images and Facial Videos
Description: 2D and 3D still and video images obtained from each patient before surgery.
Study NCT02026791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: * The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted.
Study NCT02026791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme-LMA
Description: * The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted.
Study NCT02445040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Babylog VN500 in HFOV Mode
Description: Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
Study NCT01873170 — intervention group
Intervention type: DRUG
Intervention: levonorgestrel exposure
Study NCT01873170 — intervention group
Intervention type: DRUG
Intervention: DMPA exposure
Study NCT01873170 — intervention group
Intervention type: DRUG
Intervention: etonogestrel exposure
Study NCT01873170 — intervention group
Intervention type: DEVICE
Intervention: IUD insertion
Study NCT01873170 — intervention group
Intervention type: DEVICE
Intervention: subdermal contraceptive implant insertion
Study NCT03021356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic xenograft
Description: After randomization, the aortic xenograft is implanted in the standard fashion
Study NCT00648128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral tablet
Study NCT00648128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: single-dose 500 mg immediate-release oral dose'
Study NCT02486289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
Study NCT02486289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NBMI Placebo
Study NCT03220399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-1 (P)
Description: 1capsule, single oral dosing
Study NCT03220399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-2 (T)
Description: 1tablet, single oral dosing
Study NCT03220399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1603-1 and NVP-1603-2 (P+T)
Description: 1capsule and 1tablet co-administration, oral single dosing
Study NCT01301391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib Maleate
Description: 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity.
Study NCT02133599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IOHEXOL
Description: Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
Study NCT02423681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoSmart
Description: Heated humidification as first intention (HH1st) with ThermoSmart
Study NCT02005029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Study NCT02005029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02801500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
Study NCT02801500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Anastomosis
Description: A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
Study NCT00761410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P.F.C. Sigma RP-F Total Knee Replacement
Description: An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
Study NCT03781362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-100
Description: CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
Study NCT03781362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
Study NCT03033602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written exposure therapy
Description: five sessions of writing about traumatic experience.
Study NCT03033602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT, cognitive only
Description: 12 sessions of cognitive therapy related to traumatic experience.
Study NCT03048292 — intervention group
Intervention type: OTHER
Intervention: Acute Endovascular Stroke Treatment
Study NCT02720198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomilnacipran
Description: treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
Study NCT02423681 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Without ThermoSmart
Description: ThermoSmart is switched off
Study NCT04237805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF-189s
Description: 20mg，40mg，80mg，120mg，160mg，210mg，once daily
Study NCT01222195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day by mouth on days 1-21 of every 28 day cycle.
Study NCT01222195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: 200 mcg subcutaneously every 2 weeks of a 28 cycle.
Study NCT02745821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Wire Certus, St. Jude Medical, USA
Description: FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered 200 mg/m² IV Q3W
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered 200 mg/m² IV Q3W
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 215
Description: Administered 15 mg/kg Q3W by IV infusion
Study NCT01966003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered 15 mg/kg Q3W by IV infusion
Study NCT03909984 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nightwatch
Description: Nocturnal monitoring for 2 months with three different seizure detection devices.
Study NCT04068350 — intervention group
Intervention type: OTHER
Intervention: Pain questionnaire
Description: Pain questionnaire, 3 months after surgery
Study NCT03645967 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReadyCleanse Cloths
Description: ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
Study NCT05976204 — intervention group
Intervention type: PROCEDURE
Intervention: ToF primary repair
Description: ToF primary repair for patients with ToF
Study NCT02235246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
Study NCT02235246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
Study NCT04492358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)
Study NCT04492358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone 60 mg/day, in a single dose, during 3 days
Study NCT04492358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: The standard treatment used in each site will be administered to the patients assigned to the control group.
Study NCT03773458 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: An artificial system for the screening of scoliosis
Description: An artificial intelligence to make evaluation of scoliosis using back images
Study NCT02082925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient has to get up his hand when he defined his dyspnea threshold during 6MWT